Loading
Governments promised in advance to buy vaccines that did not yet exist, and they got made. The same promise could be made for a drug against a target everyone has given up on.
Advance market commitments worked for pneumococcal vaccines and shaped COVID-19 vaccine supply. Applied to undruggable oncology targets, a public or philanthropic funder would commit to purchase a defined volume at a defined price for the first agent meeting a pre-specified efficacy bar against a designated target such as KRAS G12D in pancreatic cancer or gain-of-function mutant p53, with access conditions attached.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers, TP53.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers, TP53.
Shares Incentives reward me-too drugs and marginal gains, Funding follows fashion, not burden, Pancreatic ductal adenocarcinoma.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers, Pancreatic ductal adenocarcinoma.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares The undruggable drivers, Incentives reward me-too drugs and marginal gains, TP53, KRAS.